Table 6.

Network structure: safety at the longest available follow‐up

	Laser	Aflibercept	Bevacizumab	Pegaptanib	Ranibizumab	Sham	Overall
SSAE	9	3	6	2	10	5	18
	1013	556	410	186	1303	528	4229
ATC*	10	3	4	2	8	2	15
	824	846	330	188	1113	184	3718
Death	11	3	4	2	10	3	17
	903	846	333	188	1521	434	4455

For each safety outcome, numbers in the table are the total number of studies (upper line for each outcome) and the total number of eyes (lower line for each outcome), as available by treatment and measured at the longest available follow‐up.

(*) combined incidence of (1) cardiovascular, hemorrhagic, and unknown death; (2) nonfatal MI; and (3) nonfatal stroke.